GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Mabwell Shanghai Bioscience Co 688062.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

21.73

-1.59%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥662.5m

FY2017FY2025

Net income

−CN¥970.2m

FY2017FY2025

Free cash flow

−CN¥446.7m

FY2017FY2025

Shareholders' equity

CN¥349.5m

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
RevenueCN¥662.5mCN¥199.8mCN¥127.8mCN¥27.7mCN¥16.2mCN¥5.3mCN¥29.4mCN¥37.4mCN¥4.6m
Research and developmentCN¥977.0mCN¥782.9mCN¥835.8mCN¥758.6mCN¥622.5mCN¥581.3mCN¥363.0mCN¥169.1mCN¥107.3m
Operating income−CN¥873.7m−CN¥1.01bn−CN¥1.05bn−CN¥958.1m−CN¥769.5m−CN¥643.6m−CN¥928.0m−CN¥236.8m−CN¥106.3m
Net income−CN¥970.2m−CN¥1.04bn−CN¥1.05bn−CN¥955.2m−CN¥769.6m−CN¥642.5m−CN¥927.9m−CN¥225.2m−CN¥102.7m
Diluted earnings per share-2.42-2.59-2.67-2.62-2.56-2.12-2.31-0.56-0.26

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assetsCN¥4.56bnCN¥4.28bnCN¥4.46bnCN¥4.62bnCN¥1.60bnCN¥1.64bnCN¥1.07bnCN¥891.9mCN¥636.3m
Cash and short-term investmentsCN¥1.53bnCN¥1.20bnCN¥1.67bnCN¥2.55bnCN¥96.5mCN¥547.9mCN¥40.8mCN¥27.3mCN¥69.4m
Total liabilitiesCN¥3.99bnCN¥2.72bnCN¥1.88bnCN¥1.11bnCN¥586.7mCN¥168.4mCN¥314.9mCN¥1.02bnCN¥552.9m
DebtCN¥2.97bnCN¥2.07bnCN¥1.26bnCN¥774.5mCN¥334.6mCN¥50.0m———
Shareholders' equityCN¥349.5mCN¥1.57bnCN¥2.58bnCN¥3.52bnCN¥1.01bnCN¥1.47bnCN¥756.6m−CN¥141.0mCN¥83.4m
Shares outstanding402m403m394m365m300m303m402m402m402m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−CN¥289.0m−CN¥956.4m−CN¥780.2m−CN¥719.2m−CN¥422.4m−CN¥515.0m−CN¥354.4m−CN¥155.5m−CN¥94.4m
Capital spending−CN¥157.7m−CN¥330.1m−CN¥499.9m−CN¥545.0m−CN¥217.5m−CN¥130.6m−CN¥185.2m−CN¥224.6m−CN¥169.2m
Free cash flow−CN¥446.7m−CN¥1.29bn−CN¥1.28bn−CN¥1.26bn−CN¥639.9m−CN¥645.6m−CN¥539.5m−CN¥380.1m−CN¥263.6m
Dividends paid−CN¥78.4m−CN¥66.1m−CN¥34.1m−CN¥13.1m−CN¥788,929−CN¥1.0m———

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥185.0mCN¥127.6mCN¥96.7mCN¥464.7mCN¥56.4mCN¥44.8mCN¥58.7mCN¥25.6m
Operating income−CN¥241.1m−CN¥197.8m−CN¥436.2m−CN¥30.5m−CN¥261.4m−CN¥275.1m−CN¥339.1m−CN¥239.5m
Net income−CN¥279.8m−CN¥241.9m−CN¥372.5m−CN¥46.3m−CN¥259.6m−CN¥291.7m−CN¥349.8m−CN¥249.1m
Diluted earnings per share-0.70-0.60-0.93-0.12-0.65-0.73-0.87-0.62
Cash from operations——−CN¥186.0m−CN¥68.0mCN¥182.0m−CN¥216.0m−CN¥287.0m−CN¥206.0m
Capital spending−CN¥16.0m−CN¥44.0m−CN¥26.0m−CN¥44.0m−CN¥51.0m−CN¥35.0m−CN¥103.0m−CN¥58.0m
Free cash flow——−CN¥212.0m−CN¥112.0mCN¥131.0m−CN¥251.0m−CN¥390.0m−CN¥264.0m
Total assetsCN¥5.29bnCN¥4.57bnCN¥4.56bnCN¥4.53bnCN¥4.47bnCN¥4.19bnCN¥4.28bnCN¥4.50bn
Cash and short-term investments——CN¥1.53bnCN¥1.48bnCN¥1.39bnCN¥1.13bnCN¥1.20bnCN¥1.59bn
DebtCN¥1.55bnCN¥1.45bnCN¥2.81bnCN¥1.48bnCN¥1.97bnCN¥2.04bnCN¥1.93bnCN¥1.89bn
Shareholders' equityCN¥873.5mCN¥106.8mCN¥349.5mCN¥761.1mCN¥818.1mCN¥1.28bnCN¥1.57bnCN¥1.92bn

Financial ratios

Data as of 1 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-131.9%-505.8%-823.4%-3455.5%-4742.1%-12139.3%
Net margin-146.4%-522.5%-824.1%-3445.0%-4742.9%-12118.5%
Return on equity-277.6%-66.5%-40.8%-27.2%-76.1%-43.7%
Return on assets-21.3%-24.4%-23.6%-20.7%-48.2%-39.2%
Free cash flow yield-1.2%-5.7%-2.6%-1.8%-2.5%-4.7%
Revenue growth231.6%56.3%361.0%70.9%206.0%-82.0%
Earnings growth-7.1%-0.9%10.3%24.1%19.8%-30.8%
Current ratio0.90x1.11x2.51x6.24x0.91x4.00x
Debt to equity8.03x1.23x0.42x0.17x0.14x0.03x
Equity ratio7.7%36.7%58.0%76.1%63.4%89.7%
Interest coverage-9.59x-17.44x-78.86x-93.06x-117.74x-561.73x
R&D as a share of sales147.5%391.9%653.8%2735.9%3836.5%10964.0%
Buybacks as a share of market value0.4%-2.4%-7.8%-21.7%1.1%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue188.0%162.6%—
Operating income-3.0%6.3%—
Net income0.5%8.6%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings-15.9-7.8-12.2-5.5
Price to sales23.340.8100.7190.3

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.